Category : Healthcare and Pharmaceuticals | Published at : February-2021 | Delivery Format : PDF | Status: Published | Pages : 190
The market for autoinjectors is expected to grow at a CAGR of around 17.2% from 2020 to 2027 and expected to reach the market value of around US$ 137.6 Bn by 2027.
Autoinjectors or auto-injector is a medical device designed to deliver dose of a drug through the subcutaneous or intramuscular route of administration. These were initially designed to overcome hesitation associated with self-administration of the needle-based drug delivery device. These are easy to use and are intended to use for self-administration by patients or administration by untrained personnel. Moreover, the size of the injection is dependent on the drug-loaded.
Market Dynamics
The auto-injectors market is gaining growth on account of the growing prevalence of targeted therapies, rising incidence of anaphylaxis, increasing number of regulatory approvals, availability of generic versions of auto-injectors, favorable reimbursements and government support in developed and some developing economies, and increasing preference for self-administration due to ease of use. The increasing demand for prefilled and disposable auto-injectors due to their handiness, less probability of infection, and ease of use is further bolstering the market value. Furthermore, fundamental shifts from biologics to biosimilars, which are delivered through auto-injectors are factors anticipated to create potential opportunities over the forecast period from 2020 to 2027.
In contrast, the availability of alternative drug delivery modes, ongoing research, development, and launch of oral diabetic agents and oral insulin, and development of nasal epinephrine sprays are some of the prominent factors expected to hinder the growth over the forecast period.
Segment Instance of Autoinjectors Market
Home Care Settings accounted for the major revenue share in the global Autoinjectors Market
By end-use, the home care settings segment is experiencing increased demand in the global market. The bolstering demand for auto-injectors in home care settings especially from the developing economies is supporting the increased spending power of people on healthcare devices. The ease of use associated with the auto-injectors is ultimately increasing the demand for autoinjectors in home care.
North America accounted for the maximum revenue share in the autoinjectors Market
In 2019, North America leads the auto-injectors market with maximum revenue share, and the region is also projected to maintain its dominance over the forecast period from 2020 to 2027. The increasing incidences of anaphylaxis, growing prevalence of diabetes, rheumatoid arthritis, and other ailments, additionally the presence of residents with high disposable income are the factors supporting the regional market value. Moreover, the US and Canada are major contributors to the regional market value. The autoinjectors are often used in the US military to protect personnel from chemical warfare agents. The atropine and 2-PAM-Cl (pralidoxime chloride) are used for first aid against nerve agents.
Asia Pacific is anticipated to exhibit fastest growth during the estimated period from 2020 to 2027
The developing economies of the Asia Pacific region are projected to support their fastest growth over the forecast period from 2020 to 2027. The increasing disposable income and number of people with the demand for therapies that usage auto-injectors is further boosting the market growth. The rising prevalence of type 1 diabetes due to changing lifestyle and rapid urbanization is supporting the growth. Moreover, in China, around 50,000 children & adolescents below 20 years of age were living with type 1 diabetes in 2017 and the number has increased after that.
Key Market Players
The players profiled in the report include AbbVie, Inc., Amgen, Biogen Idec, Eli Lilly, Johnson & Johnson, Mylan N.V., Owen Mumford, Pfizer, Inc., Sanofi, Scandinavian Health Ltd., Teva Pharmaceutical, Ypsomed, and others.
Market Segmentation
Market By Therapy
Rheumatoid Arthritis
Multiple Sclerosis
Diabetes
Anaphylaxis
Other Therapies
Market By Usage Type
Disposable Autoinjectors
Reusable Autoinjectors
Market By Route of Administration
Subcutaneous
Intramuscular
Market By End-use
Home Care Settings
Hospitals & Clinics
Ambulatory Surgical Centers
Market By Geography
North America
- U.S.
- Canada
Europe
- U.K.
- Germany
- France
- Spain
- Rest of Europe
Asia-Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of Asia-Pacific
Latin America
- Brazil
- Mexico
- Rest of Latin America
Middle East & Africa
- GCC
- South Africa
- Rest of Middle East & Africa
Frequently Asked Questions
The market for autoinjectors is expected to reach a market value of around US$ 137.6 Bn by 2027.
The autoinjectors market is expected to grow at a CAGR of around 17.2% from 2020 to 2027.
Home Care Settings is the leading segment by end-use in the autoinjectors market
The growing prevalence of targeted therapies, rising incidence of anaphylaxis, increasing number of regulatory approvals, availability of generic versions of auto-injectors, favorable reimbursements and government support in developed and some developing economies and increasing preference for self-administration due to ease of use, increasing demand of prefilled and disposable auto-injectors are some of the major factors driving the market growth.
AbbVie, Inc., Amgen, Biogen Idec, Eli Lilly, Mylan N.V., Owen Mumford, Pfizer, Inc., Sanofi, Scandinavian Health Ltd., Teva Pharmaceutical, Ypsomed, and others are the prominent players in the autoinjectors market.
North America held the highest market share in the autoinjectors market
Asia Pacific is expected to be the fastest growing market over the forecast period
